A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 19 Feb 2018
At a glance
- Drugs Macitentan (Primary)
- Indications Portal hypertension; Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms PORTICO
- Sponsors Actelion Pharmaceuticals
- 14 Feb 2018 Planned End Date changed from 22 Jan 2018 to 1 Jan 2019.
- 11 Dec 2017 Planned End Date changed from 20 Feb 2018 to 22 Jan 2018.
- 21 Nov 2017 This trial has been completed in Germany.